- SG$39.95m
- SG$39.87m
- SG$5.91m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.22 | ||
| Price to Tang. Book | 5.43 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.6 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -74.38% | ||
| Return on Equity | -76.96% | ||
| Operating Margin | -138.02% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SG$m | 0.67 | 0.98 | 1.75 | 14.39 | 5.91 | 11.5 | n/a | 88.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IX Biopharma Ltd. is a Singapore-based specialty pharmaceutical and nutraceutical company. The Company is focused on the development, manufacturing and commercialization of innovative therapies for the treatment of acute and breakthrough pain, and other health conditions. It has developed a patented drug delivery platform technology, WaferiX. WaferiX is a novel multi-drug delivery platform comprising a highly porous, amorphous and non-ionic matrix in a solid dosage form. The Company operates through two segments: Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and medicinal cannabis products. Nutraceutical primary business activities are the sale of nutraceutical products. The Company's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.
Directors
- Yip Hang Lee CHM (67)
- Sien Lup Chew CFO (57)
- Janakan Krishnarajah COO (42)
- Chia Hsing Yee GMG (49)
- Desiree Chua OTH (30)
- Iain Cook OTH (61)
- Stephen Lim OTH (66)
- Yi Hua Tan OTH (36)
- Lee Soo Fern Gwendolin Lee SEC
- Kuan Loong Lai SEC
- Patrick Davies LED (54)
- Shing Tung Ho NED (53)
- Weng Keong Low IND (69)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 8th, 2004
- Public Since
- July 22nd, 2015
- No. of Shareholders
- 1,860
- No. of Employees
- 56
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Singapore Exchange Securities Trading Ltd- Shares in Issue
- 768,317,356
- Address
- 1 Kim Seng Promenade, 237994
- Web
- https://www.ixbiopharma.com/
- Phone
- +65 62352270
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for 42C
IX Biopharma Ltd Annual Shareholders Meeting
Similar to 42C
Haw Par
Singapore Exchange Securities Trading Ltd
Hyphens Pharma International
Singapore Exchange Securities Trading Ltd
Pharmesis International
Singapore Exchange Securities Trading Ltd
Suntar Eco-City
Singapore Exchange Securities Trading Ltd
FAQ
What is the IX Biopharma share price?
As of Today at 19:11 UTC, shares in IX Biopharma are trading at SG$0.05. This share price information is delayed by 15 minutes.
How has the IX Biopharma share price performed this year?
Shares in IX Biopharma last closed at SG$0.05 and the price had moved by -41.57% over the past 365 days. In terms of relative price strength the IX Biopharma share price has underperformed the FTSE Developed Asia Pacific Index by -41.17% over the past year.
What are the analyst and broker recommendations for IX Biopharma?
The overall consensus recommendation for IX Biopharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the IX Biopharma dividend yield?
IX Biopharma does not currently pay a dividend.
Does IX Biopharma pay a dividend?
IX Biopharma does not currently pay a dividend.
When does IX Biopharma next pay dividends?
IX Biopharma does not currently pay a dividend.
How do I buy IX Biopharma shares?
To buy shares in IX Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of IX Biopharma?
As of the previous close price of SG$0.05, shares in IX Biopharma had a market capitalisation of SG$39.95m.
Where are IX Biopharma shares listed?
Here are the trading details for IX Biopharma:
- Country of listing: Singapore
- Exchange: SES
- Ticker Symbol: 42C
What kind of share is IX Biopharma?
Based on an overall assessment of its quality, value and momentum IX Biopharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a IX Biopharma share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the IX Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IX Biopharma. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -3.77%.
As of the last closing price of SG$0.05, shares in IX Biopharma were trading -12.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the IX Biopharma PE Ratio?
The IX Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SG$0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of IX Biopharma?
IX Biopharma's management team is headed by:
- Yip Hang Lee - CHM
- Sien Lup Chew - CFO
- Janakan Krishnarajah - COO
- Chia Hsing Yee - GMG
- Desiree Chua - OTH
- Iain Cook - OTH
- Stephen Lim - OTH
- Yi Hua Tan - OTH
- Lee Soo Fern Gwendolin Lee - SEC
- Kuan Loong Lai - SEC
- Patrick Davies - LED
- Shing Tung Ho - NED
- Weng Keong Low - IND